Hartung HP - Search Results

1

Is It Too Early to Predict the Failure of Natalizumab in NMO?-Reply.

Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, Paul F, Aktas O; Neuromyelitis Optica Study Group (NEMOS). Kleiter I, et al. Among authors: hartung hp. Arch Neurol. 2012 Aug 1;69(8):1085-6. doi: 10.1001/archneurol.2012.1316. Arch Neurol. 2012. PMID: 23753805 No abstract available.

2

Neuromyelitis and more: the unfolding spectrum of aquaporin 4-related neurological diseases.

Aktas O, Hartung HP. Aktas O, et al. Among authors: hartung hp. J Neurol. 2009 Nov;256(11):1906-8. doi: 10.1007/s00415-009-5317-x. J Neurol. 2009. PMID: 19768482 No abstract available.

3

Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope.

Hartung HP, Aktas O. Hartung HP, et al. Ann Neurol. 2009 Oct;66(4):429-32. doi: 10.1002/ana.21880. Ann Neurol. 2009. PMID: 19847907 No abstract available.

4

Development of oral cladribine for the treatment of multiple sclerosis.

Hartung HP, Aktas O, Kieseier B, Giancarlo Comi GC. Hartung HP, et al. J Neurol. 2010 Feb;257(2):163-70. doi: 10.1007/s00415-009-5359-0. J Neurol. 2010. PMID: 19921304 Review.

5

Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis.

Aktas O, Kieseier B, Hartung HP. Aktas O, et al. Among authors: hartung hp. Trends Neurosci. 2010 Mar;33(3):140-52. doi: 10.1016/j.tins.2009.12.002. Epub 2010 Jan 4. Trends Neurosci. 2010. PMID: 20045200 Review.

6

Oral therapies for multiple sclerosis: are we there yet?

Hartung HP, Aktas O. Hartung HP, et al. Lancet Neurol. 2010 May;9(5):454-7. doi: 10.1016/S1474-4422(10)70088-0. Lancet Neurol. 2010. PMID: 20398852 No abstract available.

7

Fingolimod is a potential novel therapy for multiple sclerosis.

Aktas O, Küry P, Kieseier B, Hartung HP. Aktas O, et al. Among authors: hartung hp. Nat Rev Neurol. 2010 Jul;6(7):373-82. doi: 10.1038/nrneurol.2010.76. Epub 2010 Jun 15. Nat Rev Neurol. 2010. PMID: 20551946 Review.

8

Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria.

Hartung HP, Aktas O. Hartung HP, et al. Lancet Neurol. 2011 Apr;10(4):293-5. doi: 10.1016/S1474-4422(11)70043-6. Lancet Neurol. 2011. PMID: 21397566 No abstract available.

9

Beyond axonal transection: hippocampal damage in multiple sclerosis.

Aktas O, Hartung HP. Aktas O, et al. Among authors: hartung hp. Ann Neurol. 2011 Mar;69(3):433-6. doi: 10.1002/ana.22409. Ann Neurol. 2011. PMID: 21446019 No abstract available.

10

Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis.

Buck D, Cepok S, Hoffmann S, Grummel V, Jochim A, Berthele A, Hartung HP, Wassmuth R, Hemmer B. Buck D, et al. Among authors: hartung hp. Arch Neurol. 2011 Apr;68(4):480-7. doi: 10.1001/archneurol.2011.65. Arch Neurol. 2011. PMID: 21482927

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,138 results

Search Page

Filters